Patents by Inventor Irit Sagi

Irit Sagi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240398906
    Abstract: A method of treating a cancer which is characterized by an up-regulation of expression of lysyl oxidase (LOX) and heat shock protein 70 (HSP70) is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a propeptide of lysyl oxidase (LOX), said polypeptide being devoid of LOX catalytic activity, wherein said polypeptide binds to both LOX and heat shock protein 70 (HSP70) with a EC50 of less than 100 nM.
    Type: Application
    Filed: August 14, 2024
    Publication date: December 5, 2024
    Applicants: Yeda Research and Development Co. Ltd., Ramot at Tel-Aviv University Ltd.
    Inventors: Irit SAGI, Nikolaos A. AFRATIS, Inna SOLOMONOV, Carmit LEVY, Shivang PARIKH
  • Publication number: 20240166768
    Abstract: Monoclonal antibodies for the treatment of ovarian cancer are provided also provide are uses of same. Such uses include characterizing the tumor, diagnosing it and treatment of same.
    Type: Application
    Filed: February 2, 2024
    Publication date: May 23, 2024
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Irit SAGI, Roei David MAZOR, Ziv SHULMAN
  • Publication number: 20240041992
    Abstract: The present invention relates to a method for increasing the embryo implantation rate in a mammalian uterus, by administering to the uterus of a mammal an effective amount of an extracellular matrix remodeling enzyme, as well as to a product comprising an extracellular remodeling enzyme.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 8, 2024
    Applicant: NanoCell Ltd.
    Inventors: Irit SAGI, Inna SOLOMONOV, Eldar ZEHORAI
  • Patent number: 11779636
    Abstract: The present invention relates to a method for increasing the embryo implantation rate in a mammalian uterus, by administering to the uterus of a mammal an effective amount of an extracellular matrix remodeling enzyme, as well as to a product comprising an extracellular remodeling enzyme.
    Type: Grant
    Filed: July 7, 2022
    Date of Patent: October 10, 2023
    Assignee: NanoCell Ltd.
    Inventors: Irit Sagi, Inna Solomonov, Eldar Zehorai
  • Publication number: 20220347274
    Abstract: The present invention relates to a method for increasing the embryo implantation rate in a mammalian uterus, by administering to the uterus of a mammal an effective amount of an extracellular matrix remodeling enzyme, as well as to a product comprising an extracellular remodeling enzyme.
    Type: Application
    Filed: July 7, 2022
    Publication date: November 3, 2022
    Applicant: NanoCell Ltd.
    Inventors: Irit SAGI, Inna SOLOMONOV, Eldar ZEHORAI
  • Patent number: 11400156
    Abstract: A method of treating or preventing a disease associated with a secondary infection in a subject infected with a pathogen is provided. The method comprises administering to the subject a therapeutically effective amount of an anti-pathogenic agent directed towards the pathogen and a therapeutically effective amount of an agent which down-regulates at least one extracellular matrix-associated polypeptide.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: August 2, 2022
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Dalit Talmi-Frank, Inna Solomonov, Ido Amit
  • Patent number: 11382959
    Abstract: The present invention relates to a method for increasing the embryo implantation rate in a mammalian uterus, by administering to the uterus of a mammal an effective amount of an extracellular matrix remodeling enzyme, as well as to a product comprising an extracellular remodeling enzyme.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: July 12, 2022
    Assignee: NanoCell Ltd.
    Inventors: Irit Sagi, Inna Solomonov, Eldar Zehorai
  • Publication number: 20220106405
    Abstract: An antibody comprising an antigen recognition region which binds a catalytic site of MMP-7, having complementarity determining region (CDR) amino acid sequences as set forth in: SEQ ID NOs: 3 (CDR1), 4 (CDR2) and 5 (CDR3), sequentially arranged from N to C on a light chain of the antibody; and SEQ ID NOs: 6 (CDR1), 7 (CDR2) and 8 (CDR3), sequentially arranged from N to C on a heavy chain of the antibody.
    Type: Application
    Filed: February 10, 2020
    Publication date: April 7, 2022
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Irit SAGI, Vishnu MOHAN
  • Publication number: 20220049236
    Abstract: A method of treating fibrosis in a subject in need thereof is provided. The method comprising administering to the subject a polypeptide comprising a propeptide of lysyl oxidase (LOX), the polypeptide being devoid of LOX catalytic activity, thereby treating the fibrosis in the subject, wherein the method does not comprise administration of D-penicillamine. Also provided are polypeptide compositions for use in therapy.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 17, 2022
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Irit SAGI, Nikolaos A. AFRATIS
  • Publication number: 20210162025
    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
    Type: Application
    Filed: February 3, 2021
    Publication date: June 3, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Irit SAGI, Eitan WONG, Ran AFIK
  • Patent number: 10933122
    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: March 2, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Eitan Wong, Ran Afik
  • Publication number: 20210015907
    Abstract: The present invention relates to a method for increasing the embryo implantation rate in a mammalian uterus, by administering to the uterus of a mammal an effective amount of an extracellular matrix remodeling enzyme, as well as to a product comprising an extracellular remodeling enzyme.
    Type: Application
    Filed: June 17, 2020
    Publication date: January 21, 2021
    Applicant: NanoCell Ltd.
    Inventors: Irit SAGI, Inna SOLOMONOV, Eldar ZEHORAI
  • Publication number: 20200261577
    Abstract: A method of treating or preventing a disease associated with a secondary infection in a subject infected with a pathogen is provided. The method comprises administering to the subject a therapeutically effective amount of an anti-pathogenic agent directed towards the pathogen and a therapeutically effective amount of an agent which down-regulates at least one extracellular matrix-associated polypeptide.
    Type: Application
    Filed: March 26, 2020
    Publication date: August 20, 2020
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Irit SAGI, Dalit TALMI-FRANK, Inna SOLOMONOV, Ido AMIT
  • Patent number: 10722560
    Abstract: The present invention relates to a method for increasing the embryo implantation rate in a mammalian uterus, by administering to the uterus of a mammal an effective amount of an extracellular matrix remodeling enzyme, as well as to a product comprising an extracellular remodeling enzyme.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: July 28, 2020
    Assignee: NanoCell Ltd.
    Inventors: Irit Sagi, Inna Solomonov, Eldar Zehorai
  • Patent number: 10610588
    Abstract: A method of treating or preventing a disease associated with a secondary infection in a subject infected with a pathogen is provided. The method comprises administering to the subject a therapeutically effective amount of an anti-pathogenic agent directed towards the pathogen and a therapeutically effective amount of an agent which down-regulates at least one extracellular matrix-associated polypeptide.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: April 7, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Dalit Talmi-Frank, Inna Solomonov, Ido Amit
  • Publication number: 20190343934
    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
    Type: Application
    Filed: July 25, 2019
    Publication date: November 14, 2019
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Irit SAGI, Eitan WONG, Ran AFIK
  • Patent number: 10426821
    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 1, 2019
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Eitan Wong, Ran Afik
  • Patent number: 10066024
    Abstract: A method of generating an antibody which inhibits a metalloenzyme is disclosed. The method comprises immunizing a subject with: (i) a synthetic zinc mimicry compound having structural and electronic properties similar to a catalytic domain of the metalloenzyme; and (ii) the metalloenzyme, Antibodies generated by this method are also disclosed as well as uses thereof.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: September 4, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Netta Sela-Paswell, Moran Grossman
  • Patent number: 10040868
    Abstract: An article of manufacture is disclosed which comprises at least two active agents, wherein a first of the two active agents comprises an anti-cancer agent or an antifibrotic agent and a second of the at least two active agents downregulates the activity and/or expression of lysyl-oxidase like protein-2 (LOXL-2) and which is capable of altering the structure of the extracellular matrix.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: August 7, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Moran Grossman, Nir Ben-Chetrit
  • Publication number: 20180133293
    Abstract: The present invention relates to a method for increasing the embryo implantation rate in a mammalian uterus, by administering to the uterus of a mammal an effective amount of an extracellular matrix remodeling enzyme, as well as to a product comprising an extracellular remodeling enzyme.
    Type: Application
    Filed: April 1, 2016
    Publication date: May 17, 2018
    Inventors: Irit SAGI, Inna SOLOMONOV, Eldar ZEHORAI